Biotech News
Related news
MGTXMeiraGTx2026-08-06 20:30 EST
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MGTXMeiraGTx2026-08-13 12:00 EST
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
PRQRProQR Therapeutics2026-09-23 12:00 EST
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
CRSPCRISPR Therapeutics2026-09-08 12:30 EST
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
OKYOOKYO Pharma2026-09-08 11:00 EST
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
NTLAIntellia2026-09-04 12:00 EST
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
SGHTSight Sciences2026-09-01 20:05 EST
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15
SRPTSarepta Therapeutics2026-08-31 20:30 EST
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
EDITEditas Medicine2026-08-04 20:15 EST
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
GSKGSK plc2026-07-29 09:08 EST
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
MeiraGTx
Genetic Medicines Company MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions. Its vertically integrated model spans vector design, clinical development, and commercial manufacturing. Bota-Vec Botaretigene sparoparvovec is an AAV gene therapy for X-linked...
Recent company news
MGTXMeiraGTx2026-09-23 12:00 EST
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
MGTXMeiraGTx2026-08-13 12:00 EST
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
MGTXMeiraGTx2026-08-06 20:30 EST
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MGTXMeiraGTx2026-07-07 11:30 EST
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
MGTXMeiraGTx2026-05-14 20:30 EST
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Stock data
- Close
- 10.66 USD
- Market cap
- 855.71M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States